Name (Synonyms) | Correlation | |
---|---|---|
drug2617 | Sham Attention Training Wiki | 1.00 |
drug608 | Canakinumab Injection 600mg Wiki | 1.00 |
drug292 | Attention Training Program Wiki | 1.00 |
drug2650 | Social ABCs Wiki | 1.00 |
drug2966 | Treatment As Usual Wiki | 1.00 |
drug2176 | Placebos Wiki | 0.24 |
Name (Synonyms) | Correlation | |
---|---|---|
D001321 | Autistic Disorder NIH | 0.38 |
D000067877 | Autism Spectrum Disorder NIH | 0.33 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000717 | Autism HPO | 0.38 |
HP:0000729 | Autistic behavior HPO | 0.33 |
There is one clinical trial.
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in patients with COVID-19 infection. These results will lead to and inform a Phase III randomized placebo-controlled trial.
Description: Number of days
Measure: Time to clinical improvement up to day 14, defined as the time in days from randomization to either an improvement of two points on a seven-category ordinal scale or discharge from the hospital, whichever occurs first. Time: Up to day 14Description: Number of days
Measure: Mortality at day 28 Time: Up to day 28